Fa Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fa Yang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Weihong Wen
School of Life Sciences and Technology Northwestern Polytechnical University Xi'an China
53 shared publications - Weijun Qin
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
48 shared publications - Changhong Shi
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
42 shared publications - Donghui Han
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
42 shared publications - Hongji Li
Department of Urology, Xijing Hospital, Air Force Medical University, Xi’an, China
42 shared publications - Jingliang Zhang
Department of Urology, Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi, China
42 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Cell & Bioscience
Endosialin-positive stromal cells promote colorectal cancer progression by upregulating VEGF-driven angiogenesis
- 2 November 2026
- Published by Springer Nature in Cell & Bioscience
Open AccessEndosialin-positive stromal cells promote colorectal cancer progression by upregulating VEGF-driven angiogenesis
- Open Access
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1959437
Evolution of vascular normalization strategies: from anti-angiogenesis to remodeling the tumor microenvironment
Although anti-angiogenic therapy has been widely used in the treatment of solid tumors, angiogenesis inhibition alone frequently induces acquired resistance and exacerbates tumor hypoxia, paradoxically promoting tumor progression. The concept of tumor vascular normalization has offered a new perspective to address this dilemma, shifting the therapeutic strategy from “vessel destruction” to “vessel repair.” This review systematically elucidates the pathological characteristics of aberrant tumor vasculature and the cascading responses driven by these abnormalities. We summarize the molecular regulatory networks underlying vascular normalization across multiple dimensions, including VEGF signaling, hypoxia-inducible factors, extracellular matrix remodeling, metabolic reprogramming, and immune cell coordination. On this basis, this review further explores how vascular normalization systematically reshapes the tumor immune microenvironment by alleviating immunosuppression, promoting T cell infiltration, supporting an IFN-γ-mediated positive feedback loop, and coordinating with tertiary lymphoid structure formation. Finally, we dissect the multicellular interaction networks among tumor cells, endothelial cells, pericytes, and immune cells, and propose future directions including the vascular-immune dual-biomarker system and the targeting of pericyte phenotypic switching. This review provides a systematic framework for understanding the synergistic mechanisms linking vascular normalization and immune reprogramming, and lays a foundation for optimizing combination therapeutic strategies.
- 30 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1959437
Open AccessEvolution of vascular normalization strategies: from anti-angiogenesis to remodeling the tumor microenvironment
Although anti-angiogenic therapy has been widely used in the treatment of solid tumors, angiogenesis inhibition alone frequently induces acquired resistance and exacerbates tumor hypoxia, paradoxically promoting tumor progression. The concept of tumor vascular normalization has offered a new perspective to address this dilemma, shifting the therapeutic strategy from “vessel destruction” to “vessel repair.” This review systematically elucidates the pathological characteristics of aberrant tumor vasculature and the cascading responses driven by these abnormalities. We summarize the molecular regulatory networks underlying vascular normalization across multiple dimensions, including VEGF signaling, hypoxia-inducible factors, extracellular matrix remodeling, metabolic reprogramming, and immune cell coordination. On this basis, this review further explores how vascular normalization systematically reshapes the tumor immune microenvironment by alleviating immunosuppression, promoting T cell infiltration, supporting an IFN-γ-mediated positive feedback loop, and coordinating with tertiary lymphoid structure formation. Finally, we dissect the multicellular interaction networks among tumor cells, endothelial cells, pericytes, and immune cells, and propose future directions including the vascular-immune dual-biomarker system and the targeting of pericyte phenotypic switching. This review provides a systematic framework for understanding the synergistic mechanisms linking vascular normalization and immune reprogramming, and lays a foundation for optimizing combination therapeutic strategies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- Open Access
- 30 April 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
CircRPPH1 promotes hepatocellular carcinoma progression through inhibiting PPARα transcription and accelerating its ubiquitination and degradation
Background: Hepatocellular carcinoma (HCC) is a prominent cause of cancer-related mortality globally. It is urgently necessary to elucidate the pathogenesis of HCC and develop novel therapeutic strategies. Although certain circular RNAs (circRNAs) act as oncogenic drivers in HCC progression, the underlying mechanisms remain poorly understood. Methods: CircRNA-miRNA-mRNA network was established to screen potential circRNAs that were associated with HCC progression. CCK8, colony formation, EdU staining, wound healing, transwell assay and xenograft models were implemented to investigate the role of circRPPH1 in HCC progression. RNA-seq, luciferase reporter assays, Turbo-ID, mass spectrometry, co-immunoprecipitation and RNA-binding protein immunoprecipitation assays and rescue experiments were employed to determine the underlying molecular mechanism. Results: CircRPPH1 was significantly upregulated in HCC tissues and it promoted HCC progression both in vitro and in vivo. The elevated circRPPH1 expression in HCC was due to its increased stability, which was mediated by m 6 A methylation. CircRPPH1 could suppress the level of PPARα to promote HCC progression. Mechanistically, we found that circRPPH1 sponged miR-7845-5p to upregulate the expression of SOX4, which inhibited the transcription of PPARα. CircRPPH1 could also competitively bind with USP1, resulting in increased ubiquitination and degradation of PPARα. We also demonstrated that circRPPH1-ASOs could effectively inhibit HCC growth in vivo. Conclusions: CircRPPH1 is a tumor-promoting circRNA, which inhibits PPARα transcription through miR-7845-5p/SOX4 axis and accelerates its ubiquitination and degradation through competitively binding with USP1. These findings suggest that circRPPH1 may serve as a promising therapeutic target for HCC treatment.
- 30 April 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessCircRPPH1 promotes hepatocellular carcinoma progression through inhibiting PPARα transcription and accelerating its ubiquitination and degradation
Background: Hepatocellular carcinoma (HCC) is a prominent cause of cancer-related mortality globally. It is urgently necessary to elucidate the pathogenesis of HCC and develop novel therapeutic strategies. Although certain circular RNAs (circRNAs) act as oncogenic drivers in HCC progression, the underlying mechanisms remain poorly understood. Methods: CircRNA-miRNA-mRNA network was established to screen potential circRNAs that were associated with HCC progression. CCK8, colony formation, EdU staining, wound healing, transwell assay and xenograft models were implemented to investigate the role of circRPPH1 in HCC progression. RNA-seq, luciferase reporter assays, Turbo-ID, mass spectrometry, co-immunoprecipitation and RNA-binding protein immunoprecipitation assays and rescue experiments were employed to determine the underlying molecular mechanism. Results: CircRPPH1 was significantly upregulated in HCC tissues and it promoted HCC progression both in vitro and in vivo. The elevated circRPPH1 expression in HCC was due to its increased stability, which was mediated by m 6 A methylation. CircRPPH1 could suppress the level of PPARα to promote HCC progression. Mechanistically, we found that circRPPH1 sponged miR-7845-5p to upregulate the expression of SOX4, which inhibited the transcription of PPARα. CircRPPH1 could also competitively bind with USP1, resulting in increased ubiquitination and degradation of PPARα. We also demonstrated that circRPPH1-ASOs could effectively inhibit HCC growth in vivo. Conclusions: CircRPPH1 is a tumor-promoting circRNA, which inhibits PPARα transcription through miR-7845-5p/SOX4 axis and accelerates its ubiquitination and degradation through competitively binding with USP1. These findings suggest that circRPPH1 may serve as a promising therapeutic target for HCC treatment.